For the quarter ending 2025-06-30, ADAP made $13,677K in revenue. -$30,340K in net income. Net profit margin of -221.83%.
| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 13,677 | 7,285 | -75,926* | 40,901 |
| Selling, general and administrative | 18,485 | 23,282 | 23,430* | 21,277 |
| Research and development | 22,979 | 28,857 | 48,076* | 34,304 |
| Impairment of long-lived assets | - | - | 2,600* | - |
| Cost of goods sold | 2,501 | 879 | 18* | - |
| Total operating expenses | 43,965 | 53,018 | 74,124* | 55,581 |
| Interest income, debt securities, available-for-sale, operating | - | - | - | 2,096 |
| (loss)/profit from operations | -30,288 | -45,733 | -150,050* | -14,680 |
| Other income (expense), net | 1,289 | -305 | 2,168* | -3,093 |
| Interest income | 233 | 910 | 1,649* | - |
| Interest expense | 962 | 1,881 | 896* | 1,109 |
| (loss)/profit before income tax expense | -29,728 | -47,009 | -147,129* | -16,786 |
| Income tax expense | 612 | 575 | 1,541* | 831 |
| Net (loss)/profit attributable to ordinary shareholders | -30,340 | -47,584 | -148,670 | -17,617 |
| Basic EPS | -0.02 | -0.03 | -0.101 | -0.01 |
| Diluted EPS | -0.02 | -0.03 | -0.103 | -0.01 |
| Basic Average Shares | 1,584,522,868 | 1,542,159,622 | 1,473,286,742 | 1,534,613,977 |
| Diluted Average Shares | 1,584,522,868 | 1,542,159,622 | 1,447,634,805 | 1,534,613,977 |
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)